Under one in 10 individuals who could benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it publishes its inaugural recommendations on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just availability to this class of drugs.
According to estimates, over two billion will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that obesity is a chronic disease that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to universal availability to the treatments that can aid individuals in losing substantial body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Despite the current most favorable outlook, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of those who need them, per the WHO.
The advice calls on governments and firms to widen access, by approaches including licensing agreements.
A patent on semaglutide – the primary component of a leading brand – is scheduled to end in several nations in 2026.
The Way Obesity Drugs Work
The injections replicate a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so people consume fewer calories.
People usually begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Evidence indicates patients may regain a significant portion within a year of stopping the medication, when their usual hunger resume.
To be carrying excess weight elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
